Novartis AG has presented detailed data on its latest multiple sclerosis drug ofatumumab which the company believes will provide a more convenient treatment for patients than Roche's rival therapy Ocrevus.
Having published positive topline results last month, Novartis presented the full data set from the Phase III ASCLEPIOS I and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?